ALZCUR Stock Overview
A pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AlzeCure Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.86 |
| 52 Week High | SEK 5.22 |
| 52 Week Low | SEK 1.60 |
| Beta | 0.26 |
| 11 Month Change | -4.38% |
| 3 Month Change | 6.00% |
| 1 Year Change | -63.48% |
| 33 Year Change | -79.84% |
| 5 Year Change | -57.16% |
| Change since IPO | -83.14% |
Recent News & Updates
Recent updates
We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth
Dec 02
Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth
Jul 20Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?
Oct 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jan 03Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jul 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Mar 28Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares
Feb 03We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate
Dec 13Shareholder Returns
| ALZCUR | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -5.1% | -1.8% | -4.2% |
| 1Y | -63.5% | 73.0% | 12.5% |
Return vs Industry: ALZCUR underperformed the Swedish Pharmaceuticals industry which returned 82.3% over the past year.
Return vs Market: ALZCUR underperformed the Swedish Market which returned 17% over the past year.
Price Volatility
| ALZCUR volatility | |
|---|---|
| ALZCUR Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ALZCUR has not had significant price volatility in the past 3 months.
Volatility Over Time: ALZCUR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Martin Jönsson | www.alzecurepharma.se |
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications.
AlzeCure Pharma AB (publ) Fundamentals Summary
| ALZCUR fundamental statistics | |
|---|---|
| Market cap | SEK 163.79m |
| Earnings (TTM) | -SEK 37.43m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs ALZCUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALZCUR income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 37.43m |
| Earnings | -SEK 37.43m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 26, 2024
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALZCUR perform over the long term?
See historical performance and comparison